Preclinical data shows a potential for eRapa™ to prevent the progression and recurrence of multiple types of cancer. In particular, we are focused on the treatment of early stage prostate cancer and Familial Adenomatous Polyposis (FAP).
Early Stage Prostate Cancer
• Prostate cancer is the most common cancer in men; currently ~3M men are living with prostate cancer in US and prostate cancer deaths exceed 29,000 in the US annually
• ~80% of newly diagnosed cases are early stage – eRapa target
• Men with early stage cancers (Gleason <7) under active surveillance have no effective therapies to slow or prevent cancer progression
• eRapa global market forecast: $1 billion
A majority of men elect premature surgical and/or radiation treatment regardless of the disease severity. 90% of treated patients experience erectile dysfunction, impotency, bowel distress, and other side effects. There are currently no approved medical therapies that have been shown to decrease the rate of progression for men under active surveillance.
• U.S. Incidence: 165,000/yr
• Global Incidence: 1.1 million/yr
• U.S. Prevalence: >3 million men
• Positioning: Preventive for men with low risk Gleason Score <7
• Phase 1b trial is ongoing and currently enrolling
Familial Adenomatous Polyposis (FAP)
• Genetic condition that increases the lifetime risk of colon cancer from ~20% to nearly 100%
• Disease presents as hundreds to thousands of polyps growing in the colon and rectum, usually starting in an individual’s mid-teens
• The polyps are nearly 100% certain to develop into colon or rectal cancer by age 40
• No approved pharmaceutical treatments exist for FAP
• Current standard of care is colon and bowel resection to avoid progression to colon cancer
• US Prevalence: 50,000 cases (Designated a rare disease)
• Proven effect in preclinical mouse model
• Orphan Drug candidate
• Targeted delivery of the active pharmaceutical ingredient to the lower intestines